Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.45 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16364921 | 0.83 | TLR8 (0.50) | TLR8ARG1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL2960305 | 0.81 | ALPL (0.50) | SMN1; SMN2GAAKDM4EKMT2AALDH1A1 | |
| SCHEMBL12145480 | 0.79 | ARG1 (0.41) | TLR8ARG1TYMPFPR2KCNH2 | |
| SCHEMBL938206 | 0.78 | ARG1 (0.53) | TLR8ARG1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL3582565 | 0.78 | FPR2 (0.43) | SMN1; SMN2GAAKDM4EKMT2AALDH1A1 | |
| SCHEMBL3594313 | 0.77 | GFER (0.56) | SMN1; SMN2GAAKMT2AALDH1A1POLB | |
| SCHEMBL4963238 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2GAAKDM4EKMT2AALDH1A1 | |
| SCHEMBL5765600 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2GAAKDM4EKMT2AALDH1A1 | |
| SCHEMBL3581846 | 0.76 | SMN1; SMN2 (0.39) | SMN1; SMN2GAAKDM4EKMT2AALDH1A1 | |
| SCHEMBL13072246 | 0.76 | SMN1; SMN2 (0.39) | SMN1; SMN2GAAKDM4EKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368342-B3 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | TLR8 2515/4885ARG1 4224/4885SMN1; SMN2 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.